A blinded crossover study design to evaluate midazolam as an adjunct for equine standing sedation for routine oral examinations.
Authors: Best Amber T K, Morgan Jessica M, Burgy Clara L D, Flynn Harriet, Barter Linda S, Cassano Jennifer M
Journal: Journal of equine veterinary science
Summary
Midazolam administration prior to a standard detomidine and butorphanol standing sedation protocol produced no statistically significant improvement in sedation quality for routine equine oral examinations, despite promising trends toward reduced tongue movement and improved speculum acceptance. Twelve horses received both treatment and placebo injections in randomised crossover design across two separate examinations at least one week apart, with a blinded veterinarian scoring multiple behavioural parameters including ataxia, head position stability, resistance to manipulation, and grimace-related indicators; additional sedation doses were available if required during the procedure. Although the primary outcome—demonstrable superiority of midazolam adjunction—was not achieved (P=0.3), the lack of statistically significant differences occurred alongside observable clinical trends and critically, no adverse effects were documented. For practitioners, this suggests midazolam at 0.02 mg/kg IV represents a safe addition to conventional standing protocols, potentially warranting further investigation in horses requiring more robust sedation or those showing poor response to standard regimens, though current evidence does not mandate its routine inclusion for straightforward oral work. The clinical relevance lies not in demonstrated efficacy but in confirmed safety, offering another tool for individualised sedation management in horses with anxiety or marginal cooperation during standing procedures.
Read the full abstract on PubMed
Practical Takeaways
- •Midazolam addition to standard detomidine-butorphanol sedation showed no statistically significant improvement for routine oral exams, though some subjective improvements were noted
- •The protocol appears safe with no undesired side effects, making it a viable option if clinical preference exists, but not required for effective standing sedation
- •Consider midazolam as an adjunct only if specific behavioral issues (tongue movement, head shaking) are problematic in individual horses, as routine use may not justify additional cost
Key Findings
- •No significant differences in sedation scores between midazolam (0.02 mg/kg IV) and placebo groups (P=0.3)
- •Trends toward improved sedation characteristics with midazolam including decreased tongue movement and reduced resistance to speculum acceptance
- •No adverse side effects observed with midazolam addition to detomidine and butorphanol protocol
- •Additional sedation requirements did not differ significantly between treatment and control groups